Why Oragenics, Inc. is betting on CardioDialysis technology to expand its TBI platform
Why is Oragenics, Inc. expanding into CardioDialysis for TBI treatment? Explore the strategy, risks, and future implications today.
Why Oragenics, Inc.’ ONP-002 Phase IIa progress could redefine concussion treatment pathways
Can ONP-002 become the first approved concussion drug? Explore Oragenics’ Phase IIa progress and what it means for mTBI treatment.
Alpha Cognition expands ALPHA-1062 into traumatic brain injury, but approval is still a distant goal
Alpha Cognition won a U.S. patent for ALPHA-1062 in TBI. Read why the IP matters, what it changes, and where the biggest risks still remain.
How electroCore, Inc. is strengthening the clinical case for bioelectronic medicine in trauma-related brain injury
electroCore, Inc.’s latest data could reshape bioelectronic medicine in trauma-related brain injury. Read what clinicians and industry watchers may track next.
Oragenics launches Phase IIa trial of ONP-002 as drug developers revisit traumatic brain injury therapies
Oragenics begins Phase IIa testing of ONP-002 for concussion. Discover how this trial could reshape drug development for traumatic brain injury.